Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03984747 · ClinicalTrials.gov registry record
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
A clinical trial, sponsored by Natera.
- Completed
- Registry status
- 110
- Enrollment target
NCT03984747: Completed study, sponsored by Natera.
NCT03984747 is a clinical trial that has completed, run by Natera. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03984747 has completed, sponsored by Natera.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.
Primary Outcome
The primary outcome of the assay developed in this study would be allograft rejection high risk or low risk. This assay result will be compared to the biopsy pathology report which assesses if the transplant organ is in a state of rejection, or not. We are also measuring the donor cell free DNA, which is presumably indicating of an organ being rejected or not. Alterations in the cut off of that donor derived cell free DNA level that is allocated to high risk of rejection will be explored. Sensit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2024-08-23 |
What the finished NCT03984747 record still lists
NCT03984747 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03984747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03984747 about?
NCT03984747 is a clinical study titled "Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection". This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis, called Prospera.
What is the current status of trial NCT03984747?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2018-09-14. Estimated completion is 2024-08-23.
Who is sponsoring clinical trial NCT03984747?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI